Summit Therapeutics Inc. Share-based Payment Arrangement, Accelerated Cost
Summit Therapeutics Inc. (SMMT) reported Share-based Payment Arrangement, Accelerated Cost of $7.05 million for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-10-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost · last filed 2024-10-30
- Summit Therapeutics Inc. share-based payment arrangement, accelerated cost for the quarter ending 2024-09-30 was $7.05M.
| Period end | Share-based Payment Arrangement, Accelerated Cost 3 month |
|---|---|
| 2024-09-30 | $7.05M 10-Q · filed 2024-10-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |